WINTON GROUP Ltd Purchases 17,585 Shares of Stryker Corporation $SYK

WINTON GROUP Ltd lifted its position in Stryker Corporation (NYSE:SYK) by 129.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,200 shares of the medical technology company’s stock after buying an additional 17,585 shares during the period. WINTON GROUP Ltd’s holdings in Stryker were worth $9,823,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of SYK. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new stake in Stryker during the second quarter valued at approximately $205,000. Marshall Wace LLP increased its holdings in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new position in Stryker in the second quarter worth approximately $219,000. Finally, HUB Investment Partners LLC purchased a new position in shares of Stryker during the 2nd quarter worth $253,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last three months. 4.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SYK. Wells Fargo & Company cut their price objective on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research report on Wednesday. Citizens Jmp lowered their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research report on Monday, August 3rd. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. JPMorgan Chase & Co. reduced their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $381.40.

Stryker Trading Down 0.2%

Shares of SYK stock opened at $275.99 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a fifty day simple moving average of $326.77 and a two-hundred day simple moving average of $327.62. The firm has a market capitalization of $105.86 billion, a PE ratio of 28.60, a PEG ratio of 1.73 and a beta of 0.76. Stryker Corporation has a 52-week low of $270.85 and a 52-week high of $392.95.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts predict that Stryker Corporation will post 15.03 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.3%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.